Holen Sie sich die Stockscreener-App
2.69
5.49%
0.14
Schlusskurs vom Vortag:
$2.55
Offen:
$2.63
24-Stunden-Volumen:
3.28M
Relative Volume:
1.59
Marktkapitalisierung:
$412.81M
Einnahmen:
$38.69M
Nettoeinkommen (Verlust:
$-108.95M
KGV:
-2.2004
EPS:
-1.2225
Netto-Cashflow:
$-141.09M
1W Leistung:
+10.25%
1M Leistung:
+6.32%
6M Leistung:
+14.47%
1J Leistung:
+14.47%
1-Tages-Spanne:
$2.565
$2.705
1-Wochen-Bereich:
$2.35
$2.705
52-Wochen-Spanne:
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.69 | 412.81M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine elects two directors and ratifies auditor at annual meeting - Investing.com Canada
Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting - Stock Titan
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine Inc (EDIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine Inc (EDIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Editas Medicine Inc (EDIT) Institutional Confidence - TradingKey
Editas Medicine Inc Annual Shareholders Meeting Transcript - GuruFocus
Editas Medicine Inc (EDIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com - Investing.com India
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc - GuruFocus
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici - GuruFocus
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock - Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock - Investing.com
Editas Medicine (EDIT) CFO logs small automatic tax-related share sale - Stock Titan
Editas Medicine (EDIT) CEO logs automatic, tax-related share sale - Stock Titan
Editas Medicine (EDIT) CSO sells 731 shares under automatic tax-cover plan - Stock Titan
EDIT: EDIT-401 shows durable 90% LDL and Lp(a) reduction, with clinical trials starting in 2024 - TradingView
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? - Yahoo Finance
RA Capital affiliates report 8.89M shares in Editas Medicine (EDIT) - Stock Titan
TCG Crossover group reports 9.9% stake in Editas Medicine (EDIT) after offering - Stock Titan
Commodore reports 16.05M-share position in Editas Medicine (EDIT) under 9.99% cap - Stock Titan
Editas Medicine Inc stock (US28106W1036): Q1 2026 loss narrows as Nasdaq-listed gene-editing player - AD HOC NEWS
Genome Editing Market to Reach $13.36 Billion by 2035, Growing - openPR.com
Editas Medicine Q1 2026 Earnings: Narrowing Losses on Reduced Expenses as CRISPR Pipeline AdvancesEBITDA Analysis - newsline.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - The Motley Fool
Editas Medicine Inc stock (US28106W1036): Nasdaq gene-editing share trades quietly ahead of next cat - AD HOC NEWS
EDIT (NASDAQ) insider notice: 15,000-share resale; 32,957 RSUs vested - Stock Titan
Cardiovascular in-licensing play Kardigan looking for quick path to IPO: Finance Report - biocentury.com
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference - Caledonian Record
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT) - Seeking Alpha
Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright - MarketBeat
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Analysts Issue Forecasts for Editas Medicine Q2 Earnings - MarketBeat
Editas Medicine (EDIT) Unveils Promising Data for EDIT-401 - GuruFocus
Editas Medicine (EDIT) Showcases Promising Preclinical Findings - GuruFocus
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine Announces $319.4 Million Public Offering with CRISPR Gene Editing Focus - Minichart
HC Wainwright Weighs in on Editas Medicine Q3 Earnings - MarketBeat
Editas Medicine (NASDAQ: EDIT) sells 55.6M shares with warrants to fund EDIT-401 - Stock Titan
Editas Medicine (NASDAQ: EDIT) prices equity deal, extends cash runway to 2H 2028 - Stock Titan
Editas Medicine Prices Public Offering of Shares, Warrants - Moomoo
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):